Trastuzumab: a cardiologist’s perspective
نویسنده
چکیده
162 CURRENT ONCOLOGY—VOLUME 15, NUMBER 3 Copyright © 2008 Multimed Inc. Educational service provided to physicians by an unrestricted grant from Sanofi-Aventis Introducing our new series of expert guest editorials reporting upon different aspects of practice. These are independently reviewed and supported by unrestricted educational grants from our colleagues in industry. I N V I T E D E D I T O R I A L
منابع مشابه
The Year in Cardiology 2015: Arrhythmias and Device Therapy
This review looks back at important and clinically relevant new developments in the fields of invasive electrophysiology and device therapy in 2014. Many findings do not only apply to pure electrophysiologists, but also to every clinical cardiologist’s practice. The authors have extracted the key findings of studies with potential guideline impact and put those into a clinical perspective. Look...
متن کاملمطالعه ارتباط مقاومت به تراستوزوماب با بیان نسبی میکرو‌آر‌ان‌ای ۱۴۱ (miR-141 ) در سلول‌های انسانی سرطانی پستان BT-474
Background and Aim: Resistance to trastuzumab has been a critical barrier to targeted therapy of HER 2-positive (Human Epidermal Growth Factor Receptor 2) breast cancers. MicroRNAs (miRNAs) are known as decisive core regulators of drug resistance that modulate the epithelial-to-mesenchymal transition (EMT) and cancer-related immune responses. The present study aimed at examining the expression ...
متن کاملBone morphogenic protein receptor type 1a (BMPR1A) and Caveolin-1 associated with trastuzumab resistance of breast cancer cells
Trastuzumab is a specific monoclonal antibody used for therapeutic of the human epidermal growth factor receptor 2 (HER-2) -positive metastatic breast cancer. But, resistance to trastuzumab is a major obstacle in clinical efficiency. During the past years, several studies have been done to find the mechanisms contributing to trastuzumab resistance. Previous studies have highlighted that bone m...
متن کاملAnti-cancer effects of the combined treatment of trastuzumab and decoy oligodeoxynucleotides to target STAT3 transcription factor on SK-BR-3 breast cancer cell line
Introduction: Breast cancer is the most common malignancy in the female population and is the leading cause of death. Surgery, chemotherapy, radiotherapy, and monoclonal antibody (trastuzumab) therapy are common and standard treatments for this cancer. However, there are significant limitations in the treatment of this disease by using regular methods. Given the role of transcription factors (T...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Current Oncology
دوره 15 شماره
صفحات -
تاریخ انتشار 2008